<DOC>
	<DOC>NCT00168818</DOC>
	<brief_summary>The objective of this study is to determine the comparative efficacy and safety of two oral regimens of dabigatran etexilate, compared to a standard subcutaneous regimen of enoxaparin, in prevention of venous thromboembolism in patients with primary elective total hip replacement surgery.</brief_summary>
	<brief_title>Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criteria Inclusion criteria (selected): Patients (18 years or older) scheduled to undergo a primary, unilateral, elective total hip replacement Written Informed Consent Exclusion criteria Exclusion criteria (selected): Patients with an excessive risk of bleeding, for example because of history of bleeding diathesis major surgery or trauma within the last 3 months history of haemorrhagic stroke or any of the following intracranial pathologies: bleeding, neoplasm, AV malformation or aneurysm clinically relevant bleeding or gastric / duodenal ulcer within the last 6 months treatment with anticoagulants within 7 days prior to joint replacement surgery or anticipated need during the study treatment period thrombocytopenia. Active malignant disease or current cytostatic treatment Known severe renal insufficiency Liver disease expected to have any potential impact on survival, or elevated AST or ALT &gt; 2x upper limit of normal Recent unstable cardiovascular disease or history of myocardial infarction within the last 3 months Premenopausal women who are pregnant or nursing, or are of childbearing potential and are not practising or do not plan to continue practising acceptable methods of birth control Allergy to radio opaque contrast media or iodine, heparins (incl. heparin induced thrombocytopenia) or dabigatran Contraindications to enoxaparin Participation in a clinical trial during the last 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>